对CFTR调节器的免疫性不良事件 - 一项国际调查
Ruth M Urbantat1, Laura Behan2, Sebastian Wisniewski3
1Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité - Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany; German Center for Lung Research (DZL), Associated Partner Site, Berlin, Germany; Berlin Institute of Health (BIH) at Charité - Universitätsmedizin Berlin, Germany.
对CFTR调节器治疗的免疫原性不良事件 (IAE) 可以导致CF (pwCF) 患者停止治疗. 虽然很少见,但药物过敏对个体患者来说是一个重大问题,尽管大多数IAE是暂时的.
科学领域:
- 肺部病理学 肺部病理学
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
背景情况:
- CFTR调节器疗法为患有CF的人提供了显著的好处 (pwCF).
- 免疫性反应可能需要停止治疗.
- 识别患有这些不良事件的患者至关重要.
研究的目的:
- 为了识别因疑似免疫原体不良事件 (iAE) 而不能耐受CFTR调节器治疗的CF (pwCF) 患者.
- 描述与CFTR调节器治疗相关的IAE类型和频率.
主要方法:
- 一项调查分发给ECFS CTN中心,以收集有关IAE的数据.
- 该调查评估了反应类型,包括在再暴露后发生的反应类型.
- 分析了来自28个国家的89个CF中心的数据.
主要成果:
- 报告CF中心中有84%的CFTR调节器治疗因IAEs而停止.
- 经过治疗的pwCF中,IAE影响1.1-1.7%,皮疹和肝酶升高是最常见的.
- 在IAE患者中,72%的人再次暴露,32%的人经历了第二次IAE.
结论:
- 与CFTR调节器治疗相关的免疫原性不良事件 (IAE) 大多是短暂的.
- 虽然药物过敏很少见,但对于患有CF (pwCF) 的个人来说,它非常重要.
更多相关视频
08:00Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study
Published on: April 11, 2018
06:14Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
Published on: October 15, 2017
相关概念视频
Cystic Fibrosis: Management
Sinus disease and chronic...
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
